← All Processa Pharmaceuticals, INC filings

Processa Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
PCSA
Processa Pharmaceuticals, INC
10-K/A: Processa Pharmaceuticals 10-K/A Governance Update
Processa Pharmaceuticals files an amendment to its 2025 Annual Report to provide required disclosures regarding executive compensation, governance, and director information.
NASDAQ
PCSA
Processa Pharmaceuticals, INC
10-K: Processa Pharmaceuticals Reports 2024 Results, Outlines Strategy for Next Generation Cancer Therapies
Processa Pharmaceuticals, a clinical-stage biopharmaceutical company, details its 2024 financial results and strategic focus on developing Next Generation Cancer (NGC) therapies with improved safety and efficacy profiles.
NASDAQ
PCSA
Processa Pharmaceuticals, INC
10-K: Processa Pharmaceuticals Files 10-K, Prioritizes Oncology Pipeline
Processa Pharmaceuticals' 10-K filing highlights a strategic shift towards Next Generation Chemotherapy (NGC) oncology drugs, while reporting a net loss of $11.1 million for 2023.